IL‐25 prevents and cures fulminant hepatitis in mice through a myeloid‐derived suppressor cell‐dependent mechanism

Massimiliano Sarra, Maria Laura Cupi, Roberta Bernardini, Giulia Ronchetti, Ivan Monteleone, Marco Ranalli, Eleonora Franzè, Angelamaria Rizzo, Alfredo Colantoni, Flavio Caprioli, Marco Maggioni, Alessandra Gambacurta, Maurizio Mattei, Thomas T. Macdonald, Francesco Pallone, Giovanni Monteleone – 8 April 2013 – Fulminant hepatitis (FH) is a disease characterized by massive destruction of hepatocytes with severe impairment of liver function.

Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: A population‐based cohort study

Hanns‐Ulrich Marschall, Elisabeth Wikström Shemer, Jonas F. Ludvigsson, Olof Stephansson – 8 April 2013 – Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease in pregnancy. We aimed to estimate the risk of developing hepatobiliary disease in women with ICP and the odds of developing ICP in women with prevalent hepatobiliary disease. We analyzed data of women with births between 1973 and 2009 and registered in the Swedish Medical Birth Register.

Reply

Roongruedee Chaiteerakij, William S. Harmsen, Euijung Ryu, Rosebud O. Roberts, Janet E. Olson, Terry M. Therneau, Lewis R. Roberts – 8 April 2013

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

Zobair Younossi, Francesco Negro, Lawrence Serfaty, Stanislas Pol, Moises Diago, Stefan Zeuzem, Pietro Andreone, Eric J. Lawitz, Stuart Roberts, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon‐Domanec, Bruce Coate, Ralph DeMasi, Gaston Picchio, James Witek – 4 April 2013 – Baseline homeostasis model assessment‐estimated insulin resistance (HOMA‐IR), a marker for insulin resistance, has been associated with poor virologic response to peginterferon alpha/ribavirin (PR) in chronic hepatitis C.

Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels

Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Ji‐Dong Jia, Stefan Zeuzem, Edward Gane, Yun‐Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry L.‐Y. Chan, Harry L.A. Janssen – 2 April 2013 – On‐treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginterferon (PEG‐IFN) therapy in chronic hepatitis B (CHB), but previously proposed prediction rules have shown limited external validity. We analyzed 803 HBeAg‐positive patients treated with PEG‐IFN in three global studies with available HBsAg measurements.

Subscribe to